Literature DB >> 29068273

CD59 association with infectious bronchitis virus particles protects against antibody-dependent complement-mediated lysis.

Yanquan Wei1, Yanhong Ji1, Huichen Guo1, Xiaoying Zhi1, Shichong Han1, Yun Zhang1, Yuan Gao1, Yanyan Chang1, Dan Yan1, Kangyu Li1, Ding Xiang Liu1,2, Shiqi Sun1.   

Abstract

CD59 protein functions as a negative regulator of the terminal pathway of the complement system by binding to the C8/C9 factors. To date, little is known about the role of CD59 in coronavirus infectious bronchitis virus (IBV) infection. In this study, we discovered that CD59 was downregulated in IBV-infected cells and was associated with IBV virions. This association protected IBV particles from antibody-dependent complement-mediated lysis. IBV titres in the supernatant were significantly increased when CD59 proteins were overexpressed in cells followed by IBV infection, and this observation was further supported by knockdown or cleavage of CD59. Because no considerable change in IBV N protein and viral RNA levels was detected in total cell lysates prepared from the overexpression, knockdown or cleavage of CD59 groups, our data indicated that CD59 was involved in IBV particle release and that IBV had evolved a mechanism to utilize CD59 to evade complement-mediated destruction.

Entities:  

Keywords:  CD59; Infectious bronchitis virus; complement regulator; virion lysis

Mesh:

Substances:

Year:  2017        PMID: 29068273      PMCID: PMC5845662          DOI: 10.1099/jgv.0.000962

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  29 in total

Review 1.  Complement and its role in innate and adaptive immune responses.

Authors:  Jason R Dunkelberger; Wen-Chao Song
Journal:  Cell Res       Date:  2009-12-15       Impact factor: 25.617

Review 2.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

3.  Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.

Authors:  Moanaro Biswas; John B Johnson; Sandeep R P Kumar; Griffith D Parks; Subbiah Elankumarana; Elankumaran Subbiah
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

4.  A Coronavirus E Protein Is Present in Two Distinct Pools with Different Effects on Assembly and the Secretory Pathway.

Authors:  Jason W Westerbeck; Carolyn E Machamer
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

5.  Development and characterization of a recombinant infectious bronchitis virus expressing the ectodomain region of S1 gene of H120 strain.

Authors:  Yan-Quan Wei; Hui-Chen Guo; Hu Dong; Hai-Ming Wang; Jin Xu; De-Hui Sun; Shou-Guo Fang; Xue-Peng Cai; Ding-Xiang Liu; Shi-Qi Sun
Journal:  Appl Microbiol Biotechnol       Date:  2013-11-28       Impact factor: 4.813

Review 6.  Complement in immune and inflammatory disorders: pathophysiological mechanisms.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 7.  The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.

Authors:  Xuhui Zhou; Weiguo Hu; Xuebin Qin
Journal:  Oncologist       Date:  2008-09-08

8.  The Important Role of Lipid Raft-Mediated Attachment in the Infection of Cultured Cells by Coronavirus Infectious Bronchitis Virus Beaudette Strain.

Authors:  Huichen Guo; Mei Huang; Quan Yuan; Yanquan Wei; Yuan Gao; Lejiao Mao; Lingjun Gu; Yong Wah Tan; Yanxin Zhong; Dingxiang Liu; Shiqi Sun
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

9.  Cellular proteins associated with the interior and exterior of vesicular stomatitis virus virions.

Authors:  Megan Moerdyk-Schauwecker; Sun-Il Hwang; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

10.  S1 gene-based phylogeny of infectious bronchitis virus: An attempt to harmonize virus classification.

Authors:  Viviana Valastro; Edward C Holmes; Paul Britton; Alice Fusaro; Mark W Jackwood; Giovanni Cattoli; Isabella Monne
Journal:  Infect Genet Evol       Date:  2016-02-12       Impact factor: 3.342

View more
  5 in total

Review 1.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

2.  Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised host.

Authors:  Francesca Caccuri; Serena Messali; Daria Bortolotti; Dario Di Silvestre; Antonella De Palma; Chiara Cattaneo; Anna Bertelli; Alberto Zani; Maria Milanesi; Marta Giovanetti; Giovanni Campisi; Valentina Gentili; Antonella Bugatti; Federica Filippini; Erika Scaltriti; Stefano Pongolini; Alessandra Tucci; Simona Fiorentini; Pasqualina d'Ursi; Massimo Ciccozzi; Pierluigi Mauri; Roberta Rizzo; Arnaldo Caruso
Journal:  Virus Evol       Date:  2022-05-21

Review 3.  Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection.

Authors:  Jingyou Yu; Vaibhav Murthy; Shan-Lu Liu
Journal:  Viruses       Date:  2019-11-14       Impact factor: 5.048

4.  A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity.

Authors:  Alberto Gómez-Carballa; Irene Rivero-Calle; Jacobo Pardo-Seco; José Gómez-Rial; Carmen Rivero-Velasco; Nuria Rodríguez-Núñez; Gema Barbeito-Castiñeiras; Hugo Pérez-Freixo; Miriam Cebey-López; Ruth Barral-Arca; Carmen Rodriguez-Tenreiro; Ana Dacosta-Urbieta; Xabier Bello; Sara Pischedda; María José Currás-Tuala; Sandra Viz-Lasheras; Federico Martinón-Torres; Antonio Salas
Journal:  Environ Res       Date:  2022-02-22       Impact factor: 8.431

5.  COVID-19 Salivary Protein Profile: Unravelling Molecular Aspects of SARS-CoV-2 Infection.

Authors:  Eduardo Esteves; Vera M Mendes; Bruno Manadas; Rafaela Lopes; Liliana Bernardino; Maria José Correia; Marlene Barros; Ana Cristina Esteves; Nuno Rosa
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.